ArticleBlood2023
Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma.
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
11.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 82 citations in OpenAlex.
- Article
- HNRNPU mutations redirect cell cycle control to E2F in MYC-driven lymphomas.Blood advances · 2026Article
- Regulatory factor X 7 limits Myc activity during B cell activation and suppresses Myc-dependent lymphomagenesis.Nature immunology · 2026Article
- Immune disparities in the TME of EBV+ and EBV- BL: role of reactive oxygen species generation pathways and platelet activation.Blood advances · 2026Article
- [A retrospective analysis of clinicopathological features and efficacy in 51 patients with high-grade B-cell lymphoma with 11q abnormalities].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Single-cell whole-genome sequencing reveals convergent evolution in Burkitt lymphoma.Nature communications · 2026Article
- Shared clonal origin of angioimmunoblastic T-cell lymphoma and Burkitt lymphoma arising through divergent evolution from a common precursor.Journal of hematopathology · 2026Article
- LCR-modules: a collection of workflows for cancer genome analysis.Bioinformatics (Oxford, England) · 2026Article
- Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study.Blood cancer journal · 2026Article
- [Analysis of the disease burden of Burkitt lymphoma in China from 1990 to 2021].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Burkitt Lymphoma-A Guide to Biological Features, Diagnosis and Differential Diagnosis.Cancers · 2026Review
- Multi-Modal Deep Learning-Based Model to Predict Burkitt Lymphoma Recurrence.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2026Article
- Burkitt in disguise: clonal transformation of incidentally detected gallbladder diffuse large B-cell lymphoma in a liver transplant recipient.International journal of hematology · 2025Article
- Epstein-Barr virus: biology, pathogenesis and therapy of lymphomas.Discover oncology · 2025Review
- Genome-wide mapping of EBV-induced genomic variations identifies the role of MUC19 in EBV latency.mBio · 2025Article
- High-grade B-cell lymphoma, not otherwise specified: an LLMPP study.Blood advances · 2025Article
- Novel Molecular Insights and Evolution of Less Toxic Therapeutic Strategies in Burkitt Lymphoma.Cancers · 2025Review
- Prognosis and Treatment of Plasmablastic Lymphoma in the United States: A Multicenter Retrospective Study.Research square · 2025Article
- Colorectal cancer-associated PCBP1 mutations disrupt protein stability in a dominant negative manner.bioRxiv : the preprint server for biology · 2025Article
- Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
68 authors at 20 institutions in 7 countries.
Nicole ThomasDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.
Kostiantyn DrevalDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.
Daniela S GerhardOffice of Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Laura K HiltonCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.ORCID 0000-0002-6413-6586
Jeremy S AbramsonCenter for Lymphoma, Massachusetts General Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0001-8467-9257
Richard F AmbinderDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Stefan BartaUniversity of Pennsylvania Hospital, Philadelphia, PA.
Nancy L BartlettDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0001-8470-394X
Jeffrey BethonyDepartment of Microbiology, Immunology, and Tropical Medicine, George Washington University, Washington, DC.
Kishor BhatiaLantern Pharma, Inc, Dallas, TX.
Jay BowenBiopathology Center, Nationwide Children's Hospital, Columbus, OH.ORCID 0000-0001-6861-9043
Anthony C BryanBiopathology Center, Nationwide Children's Hospital, Columbus, OH.
Ethel CesarmanDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, Cornell University, New York, NY.ORCID 0000-0003-3303-6299
Corey CasperInfectious Disease Research Institute, Seattle, WA.ORCID 0000-0002-3609-661X
Amy ChadburnDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY.
Manuela CruzDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.
Dirk P DittmerLineberger Comprehensive Cancer Center and Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC.
Maureen A DyerClinical Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD.
Pedro FarinhaCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.ORCID 0000-0001-9364-9391
Julie M Gastier-FosterBiopathology Center, Nationwide Children's Hospital, Columbus, OH.
Alina S GerrieCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.ORCID 0000-0003-4727-1425
Bruno M GrandeSage Bionetworks, Seattle, WA.ORCID 0000-0002-4621-1589
Timothy GreinerDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.ORCID 0000-0003-1470-8328
Nicholas B GrinerOffice of Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Thomas G GrossCenter for Global Health, National Cancer Institute, National Institutes of Health, Rockville, MD.
Nancy L HarrisDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
John D IrvinFoundation for Burkitt Lymphoma Research, Geneva, Switzerland.
Elaine S JaffeLaboratory of Pathology, Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0003-4632-0301
David HenryUniversity of Pennsylvania Hospital, Philadelphia, PA.
Rebecca HuppiOffice of HIV/AIDS Malignancies, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Fabio E LealPrograma de Oncovirologia, Instituto Nacional de Cancer Jose de Alencar, Rio de Janeiro, Brazil.
Michael S LeeUniversity of North Carolina at Chapel Hill, Chapel Hill, NC.
Jean Paul MartinFoundation for Burkitt Lymphoma Research, Geneva, Switzerland.
Marie-Reine MartinFoundation for Burkitt Lymphoma Research, Geneva, Switzerland.
Sam M MbulaiteyeDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD.ORCID 0000-0002-8273-9831
Ronald MitsuyasuCenter for Clinical AIDS Research and Education, University of California Los Angeles, Los Angeles, CA.
Vivian MorrisLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
Charles G MullighanDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0002-1871-1850
Andrew J MungallCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.ORCID 0000-0002-0905-2742
Karen MungallCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Innocent MutyabaUganda Cancer Institute, Kampala, Uganda.
Mostafa NoktaOffice of HIV/AIDS Malignancies, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Constance NamirembeUganda Cancer Institute, Kampala, Uganda.
Ariela NoyMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.ORCID 0000-0002-3001-4898
Martin D OgwangEMBLEM Study, St. Mary's Hospital Lacor, Gulu, Uganda.
Abraham OmodingUganda Cancer Institute, Kampala, Uganda.
Jackson OremUganda Cancer Institute, Kampala, Uganda.ORCID 0000-0002-5366-9010
German OttDepartment of Clinical Pathology, Robert-Bosch-Krankenhaus and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
Hilary PetrelloBiopathology Center, Nationwide Children's Hospital, Columbus, OH.
Stefania PittalugaLaboratory of Pathology, Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0001-7688-1439
James D PhelanLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
Juan Carlos RamosDepartment of Medicine, Division of Hematology, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL.
Lee RatnerDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO.
Steven J ReynoldsDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Paul G RubinsteinSection of Hematology/Oncology, John H. Stroger Jr Hospital of Cook County, Chicago, IL.ORCID 0000-0002-0724-461X
Gerhard SissolakTygerberg Academic Hospital and Stellenbosch University, Cape Town, South Africa.
Graham SlackCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
Shaghayegh SoudiDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.
Steven H SwerdlowDivision of Hematopathology, University of Pittsburgh School of Medicine, Pittsburgh, PA.ORCID 0000-0002-3832-3329
Alexandra Traverse-GlehenHospices Civils de Lyon, Université Lyon 1, Service d'Anatomie Pathologique, Hopital Lyon Sud France.
Wyndham H WilsonLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
Jasper WongCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.ORCID 0000-0002-8140-6517
Robert YarchoanOffice of HIV/AIDS Malignancies, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-3057-1395
Jean C ZenKlusenThe Cancer Genome Atlas, Center for Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Marco A MarraCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.ORCID 0000-0001-7146-7175
Louis M StaudtLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
David W ScottCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.ORCID 0000-0002-0435-5947
Ryan D MorinDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.ORCID 0000-0003-2932-7800
National Institutes of Health · USSpinal Cord Injury BC · CASimon Fraser University · CANational Cancer Institute · USNationwide Children's Hospital · USUganda Cancer Institute · UGCanada's Michael Smith Genome Sciences Centre · CACornell University · USHarvard University · USPennsylvania Hospital · USUniversity of North Carolina at Chapel Hill · USWashington University in St. Louis · USAPLA Health · USFrederick National Laboratory for Cancer Research · USGeorge Washington University · USInfectious Disease Research Institute · USInstituto Nacional de Câncer - INCA · BRJohn H. Stroger, Jr. Hospital of Cook County · USJohns Hopkins University · USMemorial Sloan Kettering Cancer Center · US
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MConsortium for Advancing Management and Prevention of Cancer in People with HIVUM1CA121947 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Joseph A. Sparano · 2015 to 2026
$253.7MViral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9MVironomics and Biostatistics CoreP01CA019014 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BLOSSOM A DAMANIA, NANCY JOAN RAAB-TRAUB · 1985 to 2026
$43.8MCancer Risk in Human PopulationsZIACP010136 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI PURDUE, MARK · 2009 to 2025
$36.7MEpidemiology and Natural History of Cancer-Associated VirusesZIACP010176 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MBULAITEYE, SAM M · 2009 to 2025
$33.7MInternational Center for Excellence in Research (ICER) in Uganda: Impact of ARVsZIAAI001040 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REYNOLDS, STEVEN · 2009 to 2025
$23.5MLymphoma Disease Discovery and DefintionZIASC000550 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI JAFFE, ELAINE · 2009 to 2025
$16.9MStudy of Tumor Pathogenesis and Development of Therapies for AIDS MalignanciesZIABC010885 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI YARCHOAN, ROBERT · 2009 to 2025
$15.7MTranslating genomic discoveries to improved outcomes for high risk acute leukemiaR35CA197695 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Charles G Mullighan · 2017 to 2026
$11.4MCCR NIH HHS HHSN261200800001CNCI NIH HHS 75N91019D00024NCI NIH HHS 75N91020C00003NCI NIH HHS HHSN261200800001ENCI NIH HHS HHSN261201100007INCI NIH HHS HHSN261201100063CNCI NIH HHS P01 CA019014NCI NIH HHS P30 CA021765NCI NIH HHS R35 CA197695NCI NIH HHS UM1 CA121947NHLBI NIH HHS HHSN261201100007C
Abstract
Burkitt lymphoma (BL) accounts for most pediatric non-Hodgkin lymphomas, being less common but significantly more lethal when diagnosed in adults. Much of the knowledge of the genetics of BL thus far has originated from the study of pediatric BL (pBL), leaving its relationship to adult BL (aBL) and other adult lymphomas not fully explored. We sought to more thoroughly identify the somatic changes that underlie lymphomagenesis in aBL and any molecular features that associate with clinical disparities within and between pBL and aBL. Through comprehensive whole-genome sequencing of 230 BL and 295 diffuse large B-cell lymphoma (DLBCL) tumors, we identified additional significantly mutated genes, including more genetic features that associate with tumor Epstein-Barr virus status, and unraveled new distinct subgroupings within BL and DLBCL with 3 predominantly comprising BLs: DGG-BL (DDX3X, GNA13, and GNAI2), IC-BL (ID3 and CCND3), and Q53-BL (quiet TP53). Each BL subgroup is characterized by combinations of common driver and noncoding mutations caused by aberrant somatic hypermutation. The largest subgroups of BL cases, IC-BL and DGG-BL, are further characterized by distinct biological and gene expression differences. IC-BL and DGG-BL and their prototypical genetic features (ID3 and TP53) had significant associations with patient outcomes that were different among aBL and pBL cohorts. These findings highlight shared pathogenesis between aBL and pBL, and establish genetic subtypes within BL that serve to delineate tumors with distinct molecular features, providing a new framework for epidemiologic, diagnostic, and therapeutic strategies.
Indexed as
Burkitt LymphomaEpstein-Barr Virus InfectionsLymphoma, Large B-Cell, DiffuseAdultChildHerpesvirus 4, HumanHumansMutation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.